Nectar Brands announced the launch of their digital health solutions which are set to improve patient care and access to digital health services in Australia. The company has rolled out a range of end-to-end solutions through their portfolio of brands including Cultiva (medicinal cannabis flower brand) and Polln (online telehealth clinic). Planting a new seed for the future, Nectar Brands are providing top quality personalised care, in a virtual environment.
Biomedical and electrical engineers at UNSW Sydney have developed a new way to measure neural activity using light – rather than electricity – which could lead to a complete reimagining of medical tech like nerve-operated prosthetics and brain-machine interfaces. Prof François Ladouceur, with the School of Electrical Engineering and Telecommunications at UNSW, says the multi-disciplinary team has just demonstrated in the lab what it proved theoretically shortly before the pandemic: that sensors built using liquid crystal and integrated optics technologies – dubbed ‘optrodes’ – can register nerve impulses in a living animal body.
Centivax, a broad-spectrum vaccine platform technology company, announced $10m in seed financing in a syndicate co-led by NFX and the Global Health Investment Corporation (GHIC). The funding will be used to initiate manufacturing of its broad-spectrum vaccine program in influenza for first-in-human clinical trials, and continue development of its vaccine platform tech in other critical areas of unmet global health need, including COVID-19 and HIV/AIDS.
GE Healthcare’s Pharmaceutical Diagnostics business announced an $80m investment to increase manufacturing capacity by 30% at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway. The investment is part of the firm’s broader commitment to address future demand for iodinated contrast media, used in Xray and Computed Tomography (CT) to enhance visualization of organs, blood vessels and tissues across disease pathways.
Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry research and development pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.
Informatica, an enterprise cloud data management firm, announced it is partnering with a not-for-profit healthcare provider, Mater, to help the organization modernize and accelerate data migration to the cloud to fuel trusted data for decision making and predictive analytics. Serving a network of nearly 600,000 patients annually, Mater is faced with disparate and siloed data from its health and research as well as from different systems and clinical facilities.
Macquarie Cloud Services (MCS), part of Macquarie Telecom Group, has signed a deal with a comprehensive cancer care provider, Icon Group (Icon), to manage its platforms through a Microsoft Azure environment. Since engaging MCS, Icon has navigated a global expansion with scalable services and met regulations in the pharmacy industry against a tight deadline.
Abano Healthcare, Australasia’s largest dental support organisation (DSO), leverages SnapLogic, an intelligent integration and enterprise automation solution, to power its modernisation journey. With SnapLogic’s scalable, no-code platform, Abano Healthcare, which serves roughly half-a-million patients in ANZ via brands like 1300 Smiles, Lumino The Dentists and Maven Dental, is primed to become a leading player in the health industry.
Australian Bureau of Statistics (ABS) has revealed 3,144 Australians died by suicide in 2021, compared to 3,139 in 2020. Sadly, eight to nine people die by suicide every day. There were 2,358 male suicides (18.2 deaths per 100,000) and 786 female suicide deaths (6.1 per 100,000). Suicide was the 15th leading cause of death overall in 2021. Suicide was the most common cause of death for young people aged 15-24 years. In 2021, 219 Aboriginal and Torres Strait Islander people died by suicide.
KetaMD, Inc. (“KetaMD”), a new Florida-based telemedicine company providing access to at-home ketamine treatments for people suffering from depression and related mental health conditions, is thrilled to announce the availability of its virtual platform and mobile app to residents in Florida. KetaMD is bringing safe, affordable, accessible, and reliable mental health treatment options starting in the company’s home state.